---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053551"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:18:06.257247+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma reports Q1 2024 cash of $331.5M; advances ORIC-114 and ORIC-944 trials

## Summary
- Cash and investments $331.5M as of March 31, 2024, expected to fund operations into late 2026.
- R&D expenses $22.0M in Q1 2024 vs $19.5M in Q1 2023; G&A $7.0M vs $6.2M.
- Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC with EGFR/HER2 mutations; updated data expected H1 2025.
- ORIC-944 initial Phase 1b data supports best-in-class profile; proceeding to combination with AR inhibitor in metastatic prostate cancer.
- Strengthened cash with $125M private placement in January 2024.

## SEC filing metadata
- accession: 0000950170-24-053551
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/0000950170-24-053551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/oric-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053551
- JSON: https://secwatch.observer/filing/0000950170-24-053551.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053551.txt

## Key facts
- Earnings Releases
  Oric Pharmaceuticals, Inc. reported financial results for for the quarter ended March 31, 2024.
  - Period: for the quarter ended March 31, 2024
  - Result: reported results
  source text: ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/0000950170-24-053551-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.